Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4857
+$0.0147 · +3.12%
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Latest quote
$0.4857
+$0.0147 · +3.12%
After-hours
$0.4636
−$0.0221 · -4.55%
Oct 9, 5:11 PM ET
Regular session · ET · Market data may be delayed.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Day range
Current $0.4857
52-week range
Current $0.4857
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
53
Mixed
Risk
89
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
Day range
Current $0.4857
52-week range
Current $0.4857
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 22.7K USD | — | 21.66K USD | 17.76K USD | — |
| Gross profit | −22.7K USD | — | −21.66K USD | −17.76K USD | −5.67K USD |
| Research and development | 625.48K USD | 223.72K USD | 248.1K USD | 247.92K USD | 256.05K USD |
| Selling, general, and administrative | 17.54M USD | 57.05M USD | 1.29M USD | 1.53M USD | 1.73M USD |
| Operating expenses | 18.19M USD | 57.28M USD | 1.51M USD | 1.76M USD | 1.99M USD |
| Interest income | 161 USD | 9 USD | 60 USD | 36 USD | 5.61K USD |
| Interest expense | 430.54K USD | 563.76K USD | 665.84K USD | 532.82K USD | 568.8K USD |
| Depreciation and amortization | 22.7K USD | 20.19K USD | 21.66K USD | 22.93K USD | 5.67K USD |
| Operating income | −18.19M USD | −57.28M USD | −1.54M USD | −1.78M USD | −1.99M USD |
| Net income | −18.86M USD | −58.92M USD | −1.82M USD | −2.66M USD | −2.66M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 18, 2026 | 1:25 | — | — |
Stock split | Jan 29, 2025 | 1:60,000 | — | — |
Stock split | May 23, 2023 | 1:1,000 | — | — |
Stock split | Nov 19, 2020 | 1:1,000 | — | — |
Stock split | Jun 24, 2019 | 1:500 | — | — |
Stock split | Apr 20, 2017 | 1:250 | — | — |
Effective May 18, 2026
1:25
Effective Jan 29, 2025
1:60,000
Effective May 23, 2023
1:1,000
Effective Nov 19, 2020
1:1,000
Effective Jun 24, 2019
1:500
Effective Apr 20, 2017
1:250
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
